Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?
Authors:
- 1 July 2016
- journal article
- review article
- Published by Elsevier in Transplantation Reviews
- Vol. 30 (3) , 178-186
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In VitroDrug Metabolism and Disposition, 2012
- Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I–related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantationHuman Immunology, 2010
- Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft VasculopathyThe Journal of Heart and Lung Transplantation, 2007
- Cytomegalovirus-associated allograft rejection in heart transplant patientsCurrent Opinion in Infectious Diseases, 2007
- Impact of Repetitive Episodes of Antibody-mediated or Cellular Rejection on Cardiovascular Mortality in Cardiac Transplant Recipients: Defining Rejection PatternsThe Journal of Heart and Lung Transplantation, 2006
- The Cumulative Effect of Acute Rejection on Development of Cardiac Allograft VasculopathyThe Journal of Heart and Lung Transplantation, 2006
- Statins Affect Cell-Surface Expression of Major Histocompatibility Complex Class II Molecules by Disrupting Cholesterol-Containing MicrodomainsHuman Immunology, 2005
- Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantationInternational Journal of Cardiology, 2004
- Interactions Between Cyclosporin and Lipid-Lowering DrugsDrugs, 2003
- Cardiac Transplantation in ManCirculation, 1970